JP2000514099A - 成長ホルモン分泌促進薬によるインスリン耐性の処置 - Google Patents

成長ホルモン分泌促進薬によるインスリン耐性の処置

Info

Publication number
JP2000514099A
JP2000514099A JP11504029A JP50402999A JP2000514099A JP 2000514099 A JP2000514099 A JP 2000514099A JP 11504029 A JP11504029 A JP 11504029A JP 50402999 A JP50402999 A JP 50402999A JP 2000514099 A JP2000514099 A JP 2000514099A
Authority
JP
Japan
Prior art keywords
alkyl
group
independently
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP11504029A
Other languages
English (en)
Japanese (ja)
Inventor
カーピノ，フィリップ・アルバート
チュー，チャールズ・ウォク−フン
レフカー，ブルース・アレン
パン，リディア・コデッタ
トレッドウェイ，ジュディス・リー
ザウィストスキ，マイケル・ポール
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2000514099A publication Critical patent/JP2000514099A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP11504029A 1997-06-25 1998-06-05 成長ホルモン分泌促進薬によるインスリン耐性の処置 Withdrawn JP2000514099A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
US60/050,790 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004228301A Division JP3742643B2 (ja) 1997-06-25 2004-08-04 成長ホルモン分泌促進化合物の中間体の製造方法

Publications (1)

Publication Number Publication Date
JP2000514099A true JP2000514099A (ja) 2000-10-24

Family

ID=21967444

Family Applications (2)

Application Number Title Priority Date Filing Date
JP11504029A Withdrawn JP2000514099A (ja) 1997-06-25 1998-06-05 成長ホルモン分泌促進薬によるインスリン耐性の処置
JP2004228301A Expired - Fee Related JP3742643B2 (ja) 1997-06-25 2004-08-04 成長ホルモン分泌促進化合物の中間体の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004228301A Expired - Fee Related JP3742643B2 (ja) 1997-06-25 2004-08-04 成長ホルモン分泌促進化合物の中間体の製造方法

Country Status (40)

Country Link
US (3) US6448263B1 (enExample)
EP (1) EP1000085B1 (enExample)
JP (2) JP2000514099A (enExample)
KR (1) KR20010014224A (enExample)
CN (2) CN1152049C (enExample)
AP (1) AP1145A (enExample)
AR (1) AR012256A1 (enExample)
AT (1) ATE305477T1 (enExample)
AU (1) AU747510B2 (enExample)
BG (1) BG104008A (enExample)
BR (1) BR9810477A (enExample)
CA (1) CA2294464A1 (enExample)
CO (1) CO4950621A1 (enExample)
DE (1) DE69831745T2 (enExample)
DZ (1) DZ2539A1 (enExample)
EA (1) EA002089B1 (enExample)
EG (1) EG21712A (enExample)
ES (1) ES2248899T3 (enExample)
HN (1) HN1998000088A (enExample)
HR (1) HRP980361A2 (enExample)
HU (1) HUP0001922A3 (enExample)
ID (1) ID24345A (enExample)
IL (7) IL154115A0 (enExample)
IN (1) IN189724B (enExample)
IS (1) IS5275A (enExample)
MA (1) MA24581A1 (enExample)
NO (1) NO996205D0 (enExample)
NZ (1) NZ500655A (enExample)
OA (1) OA11242A (enExample)
PA (1) PA8452601A1 (enExample)
PE (1) PE105399A1 (enExample)
PL (1) PL337659A1 (enExample)
SK (1) SK175699A3 (enExample)
TN (1) TNSN98113A1 (enExample)
TR (1) TR199903257T2 (enExample)
TW (1) TW553943B (enExample)
UA (1) UA64751C2 (enExample)
WO (1) WO1998058949A1 (enExample)
YU (1) YU70199A (enExample)
ZA (1) ZA985546B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522787A (ja) * 2013-05-28 2016-08-04 ラクオリア創薬株式会社 多形形態

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
EP1539959A2 (en) * 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
PT1828480E (pt) * 2004-12-21 2014-08-29 Hercules Inc Resinas catiónicas reactivas para aplicação como agentes de resistência à secura e à humidade em sistemas de fabricação de papel contendo iões de sulfito
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
ES2707124T3 (es) * 2014-08-05 2019-04-02 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina
TW201625613A (zh) 2014-10-31 2016-07-16 拉夸里亞創藥股份有限公司 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632B (zh) * 2024-10-09 2026-08-11 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
CA2147503A1 (en) 1992-11-06 1994-05-26 Judith M. Pisano Substituted dipeptide analogs promote release of growth hormone
SK282166B6 (sk) 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9408019A (pt) 1993-11-09 1997-08-26 Merck & Co Inc Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
AU715856B2 (en) 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6251902B1 (en) * 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522787A (ja) * 2013-05-28 2016-08-04 ラクオリア創薬株式会社 多形形態

Also Published As

Publication number Publication date
IL154111A0 (en) 2003-07-31
HUP0001922A3 (en) 2001-02-28
CO4950621A1 (es) 2000-09-01
EA199901075A1 (ru) 2000-08-28
IN189724B (enExample) 2003-04-19
ATE305477T1 (de) 2005-10-15
ID24345A (id) 2000-07-13
NZ500655A (en) 2002-02-01
TNSN98113A1 (fr) 2005-03-15
HN1998000088A (es) 1999-01-08
US6867202B1 (en) 2005-03-15
JP2005097261A (ja) 2005-04-14
PA8452601A1 (es) 2000-05-24
DE69831745T2 (de) 2006-08-31
IL154116A0 (en) 2003-07-31
CA2294464A1 (en) 1998-12-30
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
AP1145A (en) 2003-02-14
DE69831745D1 (de) 2006-02-09
IS5275A (is) 1999-11-26
AU747510B2 (en) 2002-05-16
JP3742643B2 (ja) 2006-02-08
PL337659A1 (en) 2000-08-28
IL156465A0 (en) 2004-01-04
HRP980361A2 (en) 1999-02-28
ZA985546B (en) 2000-01-10
UA64751C2 (uk) 2004-03-15
NO996205L (no) 1999-12-15
SK175699A3 (en) 2001-04-09
TR199903257T2 (xx) 2000-12-21
CN1530107A (zh) 2004-09-22
US6448263B1 (en) 2002-09-10
KR20010014224A (ko) 2001-02-26
BR9810477A (pt) 2007-05-22
TW553943B (en) 2003-09-21
US20030100561A1 (en) 2003-05-29
WO1998058949A1 (en) 1998-12-30
EG21712A (en) 2002-02-27
CN1152049C (zh) 2004-06-02
DZ2539A1 (fr) 2003-02-08
US6630487B2 (en) 2003-10-07
BG104008A (en) 2000-07-31
EP1000085B1 (en) 2005-09-28
AU7445698A (en) 1999-01-04
YU70199A (sh) 2003-01-31
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
IL154114A0 (en) 2003-07-31
ES2248899T3 (es) 2006-03-16
IL154115A0 (en) 2003-07-31
IL156465A (en) 2004-07-25
NO996205D0 (no) 1999-12-15
OA11242A (en) 2003-07-23
MA24581A1 (fr) 1998-12-31
HK1028051A1 (en) 2001-02-02
EP1000085A1 (en) 2000-05-17
CN1259140A (zh) 2000-07-05
PE105399A1 (es) 1999-11-04
EA002089B1 (ru) 2001-12-24
AR012256A1 (es) 2000-09-27

Similar Documents

Publication Publication Date Title
JP3742643B2 (ja) 成長ホルモン分泌促進化合物の中間体の製造方法
JP3511382B2 (ja) 成長ホルモン分泌促進物質
US7115628B2 (en) Bridged piperidine derivatives as melanocortin receptor agonists
AU2001288285B2 (en) Substituted piperidines as melanocortin receptor agonists
JP2000516639A (ja) 成長ホルモン分泌促進薬としてのジペプチド誘導体
MXPA99012085A (es) Tratamiento de la resistencia a la insulina

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040406

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20050126